UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) was the target of a large decrease in short interest in the month of September. As of September 30th, there was short interest totaling 3,300 shares, a decrease of 57.1% from the September 15th total of 7,700 shares. Based on an average trading volume of 64,700 shares, the short-interest ratio is presently 0.1 days. Based on an average trading volume of 64,700 shares, the short-interest ratio is presently 0.1 days.

UCB Trading Down 1.9%

Shares of OTCMKTS:UCBJY opened at $145.97 on Friday. The business’s fifty day moving average price is $126.23 and its two-hundred day moving average price is $104.28. UCB has a one year low of $71.16 and a one year high of $151.76.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on UCBJY shares. Zacks Research upgraded UCB from a “hold” rating to a “strong-buy” rating in a report on Friday, August 29th. The Goldman Sachs Group upgraded UCB to a “strong-buy” rating in a report on Wednesday, July 16th. Two research analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Strong Buy”.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.